Immunome Inc (IMNM)
Immunome Inc (IMNM) is a NASDAQ-listed biotechnology company in the healthcare sector. The company’s common stock is the listed security, so the instrument represents equity ownership in Immunome rather than a fund, note, or other product. Immunome works in antibody-focused drug research and development, with programs aimed at cancer and related therapeutic areas. Its pipeline includes candidates at different stages of study, from early research through clinical development. As a common equity security, IMNM reflects exposure to the company’s operating results, research progress, and broader biotechnology market conditions.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMNM
|
$20.68
|
-7.7% Downside
|
Fair
|
$35.42
|
58.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-11.4x
|
4.3x
|
635.5x
|
2.51 B
|
1.973 B
|
0.1%
|
95.6%
|
46.5
|
—
|
91.5%
|
